Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 333

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 333
---
 |      3.9 |
| 02/22/24 |     | Comvita Limited (NZSE:CVT)                                         |     | —                                          |     |      112.8 |     |    142.8 |     |      7.8 |     |      0.3 |
| 02/21/24 |     | China Traditional Chinese Medicine Holdings Co. Limited (SEHK:570) |     | Sinopharm Common Wealth Company Limited    |     |    3,023.8 |     |  2,555.7 |     |    348.0 |     |    189.7 |

Notes:

| (1) | Values in millions of US dollars. |

190

| (2) | Corresponding Enterprise Value multiples in tables below. |

| (3) | Source: S&P Capital IQ. |

| Date     |     | Target                                          |     | Buyer / Investor                                                                                     |     | Enterprise 
   Value($) |     |    Sales 
 (TTM)($) |     |   EBITDA 
 (TTM)($) |     |     EBIT 
 (TTM)($) |
| 01/12/24 |     | Hanmi Science Co., Ltd. (KOSE:A008930)          |     | OCI Holdings Company Ltd. (KOSE:A010060)                                                             |     |    1,735.4 |     |    962.3 |     |    115.9 |     |    109.1 |
| 10/06/23 |     | Haleon plc (LSE:HLN)                            |     | —                                                                                                    |     |   54,924.6 |     | 13,806.7 |     |  3,315.0 |     |  3,037.4 |
| 06/05/23 |     | Swedencare AB (publ) (OM:SECARE)                |     | Symrise AG (XTRA:SYI)                                                                                |     |      776.6 |     |    191.0 |     |     43.7 |     |     15.7 |
| 04/12/23 |     | Cosmax BTI, Inc. (KOSE:A044820)                 |     | —                                                                                                    |     |      359.0 |     |    471.9 |     |